tiprankstipranks
Advertisement
Advertisement

MAZE Stock Latest News

Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James
The FlyMaze Therapeutics share sell-off an ‘overreaction,’ says Raymond James
10m ago
MAZE
VRTX
Maze Therapeutics falls -33.2%
PremiumThe Fly
Maze Therapeutics falls -33.2%
2h ago
MAZE
Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’
PremiumThe Fly
Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’
2h ago
MAZE
VRTX
Maze Therapeutics price target raised to $110 from $60 at H.C. Wainwright
PremiumThe Fly
Maze Therapeutics price target raised to $110 from $60 at H.C. Wainwright
2h ago
MAZE
Maze Therapeutics reports Q4 EPS (65c), consensus (78c)
PremiumThe Fly
Maze Therapeutics reports Q4 EPS (65c), consensus (78c)
4h ago
MAZE
Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
PremiumThe FlyMaze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
4h ago
MAZE
Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
Premium
The Fly
Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
4h ago
MAZE
Maze Therapeutics adds Neil Kumar to board leadership
Premium
Company Announcements
Maze Therapeutics adds Neil Kumar to board leadership
4h ago
8K
MAZE
Block upgraded, Starbucks downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Block upgraded, Starbucks downgraded: Wall Street’s top analyst calls
7d ago
CF
EXR
Maze Therapeutics initiated with a Buy at Truist
PremiumThe Fly
Maze Therapeutics initiated with a Buy at Truist
8d ago
MAZE
Maze Therapeutics price target raised to $58 from $43 at Wedbush
PremiumThe Fly
Maze Therapeutics price target raised to $58 from $43 at Wedbush
9d ago
MAZE
Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
15d ago
LTH
NVO
Maze Therapeutics initiated with an Outperform at Mizuho
PremiumThe FlyMaze Therapeutics initiated with an Outperform at Mizuho
15d ago
MAZE
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
Premium
Ratings
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
16d ago
MAZE
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
Premium
Ratings
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
20d ago
MAZE
Maze Therapeutics price target raised to $58 from $46 at Guggenheim
PremiumThe Fly
Maze Therapeutics price target raised to $58 from $46 at Guggenheim
21d ago
MAZE
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
PremiumRatings
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
29d ago
MAZE
Maze Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Maze Therapeutics files automatic mixed securities shelf
2M ago
MAZE
Maze Therapeutics Secures New $200 Million Loan Facility
PremiumCompany Announcements
Maze Therapeutics Secures New $200 Million Loan Facility
2M ago
8K
MAZE
Buy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target
PremiumRatingsBuy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target
2M ago
MAZE
Maze Therapeutics price target raised to $46 from $37 at BTIG
Premium
The Fly
Maze Therapeutics price target raised to $46 from $37 at BTIG
2M ago
MAZE
VRTX
Maze Therapeutics price target raised to $46 from $34 at Guggenheim
Premium
The Fly
Maze Therapeutics price target raised to $46 from $34 at Guggenheim
3M ago
MAZE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >